Impact of HPV vaccination with Gardasil® in Switzerland
| Autor: | Gilbert Greub, Chahin Achtari, Massimo Bongiovanni, Jérôme Pasquier, Martine Jacot-Guillarmod, Roland Sahli |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Uterine Cervical Neoplasms
Chlamydia trachomatis medicine.disease_cause 0302 clinical medicine Human Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18 Surveys and Questionnaires Cervical cancer screening 030212 general & internal medicine Papillomaviridae Child Cervical cancer education.field_of_study biology Incidence (epidemiology) Vaccination Infectious Diseases medicine.anatomical_structure 030220 oncology & carcinogenesis Female Switzerland Research Article medicine.drug Human papillomavirus medicine.medical_specialty Adolescent Genotype PGMY-CHUV Population Anyplex II™ HPV28 lcsh:Infectious and parasitic diseases 03 medical and health sciences Internal medicine medicine Humans lcsh:RC109-216 Papillomavirus Vaccines Gardasil® education Segmented logistic regression Cervix HPV vaccine business.industry Gardasil Chlamydia Infections/diagnosis Chlamydia Infections/epidemiology Chlamydia trachomatis/genetics Chlamydia trachomatis/isolation & purification DNA Viral/genetics DNA Viral/metabolism Follow-Up Studies Human Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18/immunology Papillomaviridae/genetics Papillomaviridae/isolation & purification Papillomavirus Infections/diagnosis Papillomavirus Infections/epidemiology Papillomavirus Infections/prevention & control Papillomavirus Vaccines/immunology Switzerland/epidemiology Uterine Cervical Neoplasms/diagnosis Uterine Cervical Neoplasms/prevention & control HPV genotyping Real-time PCR Papillomavirus Infections Chlamydia Infections medicine.disease biology.organism_classification DNA Viral business |
| Zdroj: | BMC infectious diseases, vol. 17, no. 1, pp. 790 BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-10 (2017) BMC Infectious Diseases |
| Popis: | Background Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomaviruses (HPV), has been offered to 11–14 year-old schoolgirls in Switzerland since 2008. To evaluate its success and its potential impact on cervical cancer screening, HPV genotypes were examined in 18-year-old girls five years later (sub-study 1) and in outpatients participating to cervical cancer screening before and after vaccine implementation (sub-study 2). Methods For sub-study 1, 3726 females aged 18 in 2013 were invited to fill a questionnaire on personal demographics and HPV risk factors and to provide a self-collected cervicovaginal sample for HPV genotyping and Chlamydia trachomatis PCR. Personal data were evaluated by univariable and multivariable statistics. In sub-study 2, the proportion of the vaccine-type HPV among anogenital HPV was examined with archived genotyping data of 8039 outpatients participating to cervical cancer screening from 1999 till 2015. The yearly evolution of this proportion was evaluated by segmented logistic regression. Results 690 (18.5%) women participated to sub-study 1 and 327 (8.8%) provided a self-collected sample. Prevalence of Chlamydia trachomatis (4.6%) and demographics confirmed that the subjects were representative of sexually-active Swiss young women. Vaccine (five-year coverage: 77.5%) was preferentially accepted by contraceptive-pill users (P = 0.001) and samples were mainly provided by sexually-active subjects (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|